Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Preventan is a dietary supplement and nutraceutical primarily marketed for the enhancement of the immune system's first line of defense. Developed by Farmax (now part of SVUS Pharma), its core component is **ProteQuine**, a proprietary complex consisting of nucleotides, amino acids, and oligopeptides derived from bovine sources. The supplement is typically formulated as lozenges designed to be dissolved in the mouth, allowing the active ingredients to interact directly with the mucosal surfaces of the oral cavity. The primary mechanism of action involves the stimulation of **secretory immunoglobulin A (sIgA)** production on the mucous membranes, which plays a critical role in neutralizing viral and bacterial pathogens before they can penetrate the respiratory epithelium. It is frequently used for the prevention and supportive management of the common cold and other upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Preventan.